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Abstract
Background: A single nucleotide polymorphism (rs5848) located in the 39- untranslated region of GRN has recently been
associated with a risk of frontotemporal lobar degeneration (FTLD) in North American population particularly in
pathologically confirmed cases with neural inclusions immunoreactive for ubiquitin and TAR DNA-binding protein 43 (TDP-
43), but negative for tau and alpha-synuclein (FTLD-TDP).
Methodology/Principal Findings: In an effort to replicate these results in a different population, rs5848 was genotyped in
256 FTLD cases and 1695 controls from the Netherlands. Single SNP gender-adjusted logistic regression analysis revealed no
significant association between variation at rs5848 and FTLD. Fisher’s exact test, failed to find any significant association
between rs5848 and a subset of 23 pathology confirmed FTLD-TDP cases.
Conclusions/Significance: The evidence presented here suggests that variation at rs5848 does not contribute to the
etiology of FTLD in the Dutch population.
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Introduction
Frontotemporal lobar degeneration (FTLD) is the second most
common form of presenile dementia after Alzheimer’s disease
(AD), representing ,5% of all dementia cases and as much as 10–
20% of presenile dementia [1,2].
FTLD is characterized by not specific symptoms such as apathy
and lack of interest, usually followed by specific features such as
disinhibition or progressive language loss. These symptoms
gradually evolve to cognitive impairment and dementia.
Pathologically, FTLD is characterized by neural loss and gliosis in
the cortical lamina II of the frontal and temporal lobes. FTLD is
pathologically heterogeneous and can be divided in FTLD with tau-
positive inclusions (FTLD-tau), and FTLD with neural inclusions
immunoreactive for ubiquitin and TAR DNA-binding protein 43
(TDP-43), but negative for tau and alpha-synuclein (FTLD-TDP)
[3,4]. In some FTLD-TDP cases, these pathological features co-occur
with motor neuron disease (FTLD-MND) [5], which is characterized
by the degeneration of upper and/or lower motor neurons.
FTLD has a high familial incidence with up to 50% of patients
reported to have a family history of similar dementia, parkinson-
ism or MND [6,7,8,9]. It has been reported that loss of function
mutations in the gene encoding the secreted growth factor
progranulin (GRN) are a major cause of FTLD-TDP worldwide
counting for as much as 25% of familiar FTLD-TDP [10,11,12].
Recently, Rademakers and colleagues demonstrated that a single
nucleotide polymorphism (rs5848) located in the 39- untranslated
region (39-UTR) of GRN is significantly associated with the
development of FTLD, particularly in a homogeneous series of
patients with a neuropathological diagnosis of FTLD-TDP [13]. They
showed that homozygous carriers of the risk T-allele have a 3.2-fold
increased risk to develop FTLD-TDP compared with homozygous
carriers for the major C-allele. This risk was increased when excluding
those patients in which MND had been diagnosed. Moreover, since
rs5848 is located in the predicted binding site of miRNAmiR-659 and
that these small RNAs are known to posttranscriptionally modulate
expression of target mRNAs, the authors hypothesized that rs5848
increases the risk of FTLD-TDP by altering the miRNA regulation of
GRN. They successfully demonstrate that miR-659 binds more
efficiently to the GRN 39-UTR containing the risk T-allele of rs5848
resulting in a drop of GRN protein levels. As expected, no changes
were detected in the GRN mRNA levels.
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In an effort to replicate the results obtained by Rademakers and
collaborators and to confirm the role of rs5848 in modulating the
risk for FTLD, this SNP was genotyped in a large series of 287
FTLD cases (before quality control procedures) and 1695 controls
from the Netherlands [14,15].
Methods
Participants
Approval was given by the Medical Ethical Committee of the
Erasmus University, Rotterdam, the Netherlands; after written
informed consent of the patients that their information could be
stored in the hospital database and used for research.
A total of 287 patients with FTD were ascertained from an
ongoing genetic-epidemiologic study conducted in the Netherlands
since 1994 after referral to the out-clinic department of the
Erasmus Medical Center, or after visiting nursing homes and
psychogeriatric hospitals by the research physician [8,15]. Detailed
clinical history was obtained from the spouses and first-degree
relatives using a checklist of behavioral and cognitive changes, and
motor neuron signs.
The age at onset was defined as the age at which the first
symptom, compatible with FTD diagnosis, was observed by a close
relative or caretaker. During the neurological examination carried
out in all patients, special attention was paid to the presence of
extrapyramidal and motor neuron disease signs.
After genotyping, all samples presenting with mutations in
MAPT and GRN genes, those in which an autopsy did not confirm
FTLD pathology, those without a Caucasian ancestry and those
closely related to some other sample in our dataset, where
removed from further analysis. Thus, our final FTLD cohort
consisted of 256 cases of which 120 where males and 136 females.
The main age at onset was 57.73 years ranging from 28.64 to
75.95 years (SD=8.94).
Control samples consisted of 805 males and 890 females from
the Longitudinal Aging Study Amsterdam [17](LASA, http://
www.lasa-vu.nl/) with a mean age of 68.78 years at the time of
medical examination (range: 54.80 – 88.77, SD=9.40 years).
Although we are aware that the age distribution of this cohort
cannot be matched to that from the FTLD cases, a single SNP sex-
adjusted linear regression analysis in these samples considering the
age at examination as a quantitative phenotype showed that
genotypes at rs5848 are equally distributed across age (Pgenotypic=0.29).
Genotyping
Custom TaqManH MGB probes and primers from Applied
Biosystems (www.appliedbiosystems.com) were utilized to geno-
type rs5848 in all samples previously described. Primer and probes
were design with the File Builder v3.1 software (www.appliedbio-
systems.com) and genotyping was performed in a LightCycler 480
II PCR system using LightCycler 480 Probes Master mix (www.
roche.com) as per manufacturer’s instructions. For each reaction,
20 ng of genomic DNA was utilized.
Statistical analysis
All tests and estimates were performed using the PLINK toolset
for whole-genome analysis (http://pngu.mgh.harvard.edu/,pur-
cell/plink) [18].
Genotyping information at rs5848 was tested for departures
from the Hardy-Weinberg equilibrium.
Single SNP gender-adjusted logistic regression analysis was
performed to test for association between rs5848 and FTLD using
a recessive model. Besides, to test for the effect of rs5848 in FTLD-
TDP confirmed cases, a Fisher’s exact test for association was
performed.
Statistical significance for differences in age at onset was tested
using a gender-adjusted linear regression analysis and considering
age at onset as a quantitative trait. Before performing this analysis,
R v.2.7.2 software (http://cran.r-project.org/) revealed a normal
distribution of the data.
Results
In order to confirm the results obtained by Rademakers and
collaborators who described an association between rs5848 and a
risk for FTLD, especially in a subset of pathologically confirmed
FTLD-TDP patients [13], we undertook a logistic regression
analysis of variation at this locus in a large series of FTLD cases and
controls from the Netherlands.
After removing samples with mutations in MAPT or GRN genes,
those not showing a clear Caucasian ancestry, those in which an
autopsy could not confirm the existence of FTLD and those closely
related to some other individual in our FTLD cohort, our final
dataset consisted of 256 FTLD cases and 1695 controls. There
were no departures from Hardy-Weinberg equilibrium.
Given that the association described by Rademakers’ and
colleagues at rs5848 was because of an increase of TT genotype
frequency in patients compared with controls, we decided to
perform a single SNP gender-adjusted logistic regression following
a recessive model of association. Results derived from this analysis
revealed no significant association between rs5848 and FTLD
(Precessive=0.57; table 1).
In order to confirm Rademaker’s and colleagues’ results in
which they focused their analyses on a homogenous series of
patients with confirmed TDP-43-positive neuronal inclusions,
Fisher’s exact test of association was performed in a subset of our
series of 23 pathologically confirmed FTLD-TDP cases. Besides, in
an effort to replicate Rademakers’ results showing that the effect
detected was increased when individuals with confirmed MND
pathology were removed, Fisher’s exact test was repeated after the
removal of 5 patients with a confirmed MND pathology. Results
derived from these analyses failed to detect any association
between rs5848 and FTLD (table 1).
Finally, in an effort to test whether rs5848 may have an
influence on the age at onset of FTLD in our cohort, a gender-
adjusted linear regression analysis following a recessive model was
performed considering age at onset as an alternative quantitative
phenotype. No association was detected after this analysis in the
entire cases cohort (Precessive=0.50).
Discussion
Here we present the analysis of rs5848 in a large cohort of
FTLD cases and controls from the Netherlands. Variation at this
locus was previously associated with a risk of FTLD in a large series
of 339 individuals from three different subgroups of cases (Olmsted
County community-based series, ADRC-FTLD referral series and
the tertiary referral series) and 934 controls ascertained through
the Mayo Clinic at Jacksonville and Scottsdale [13,19]. The
reported association was driven by an excess of homozygous
patients for the T allele (Pgenotypic = 0.002). Analysis of variation at
this locus in our Dutch cohort showed no significant differences
between the frequency of homozygous T carriers in cases versus
controls (Precessive = 0.57). Although we cannot rule out a minimal
contribution of this locus on modeling a risk for FTLD, the sample
size of the population utilized for our statistical tests (256 FTLD
cases and 1645 controls) provides an adequate power to detect an
effect of the magnitude originally described (OR=2.9 for T/T
Variation at rs5848 and FTLD
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carriers versus T/C and C/C carriers). Thus, the evidence
presented here suggests that variation at rs5848 does not
contribute to the etiology of FTLD in the Dutch population.
We also failed to replicate Rademakers and collaborators’ results
showing an association between rs5848 and a subset of neuropatho-
logically confirmed FTLD-TDP cases from the Mayo Clinic brain
bank [13]. Given the reduced number of FTLD-TDP confirmed
cases in our series, this could be due to a type II error and thus, a role
of rs5848 on modulating a risk for this pathological subtype of the
disease cannot be discarded. However, the fact that no association
was detected in the whole FTLD series suggests otherwise.
As proposed by Mackenzie et al., who established a classification
scheme of FTLD-TDP cases based on the distribution of the
neuronal cytoplasmatic inclusions, dystrophic neurites and the
presence of neuronal intranuclear inclusions [20], our pathological
series consisted on 8 type 2 and 15 type 3 patients. Although the
lack of type 1 FTLD-FTD patients in our cohort could explain the
discrepancies observed between ours and Rademakers’ results, the
increase of TT carriers among type 1 FTLD-TDP cases detected
in the Mayo clinic series was not statistically significant after
Fisher’s exact test of association (P=0.26).
Recently, Viswanathan and collaborators investigated the role
of six different SNPs in the GRN gene (including rs5848) in a
Finnish population with AD [21]. Although no association was
found for either of the SNPs assayed, they suggest that variation in
rs5848 and two other SNPs may increase the risk for developing
AD in a gender-specific manner. Given the similarities between
FTLD and AD, logistic regression models were adjusted for
gender. However, this approach did not show any association
between rs5848 and a risk of FTLD in our population.
In a similar report as that presented herein, Rollinson and
collaborators also failed to find any association between rs5848 an
FTLD in 3 different European populations [22]. Together with
ours, these results suggest that rs5848 has no effect on modulating
a risk for FTLD in European populations, being in discordance
with those results obtained by Rademakers and colleagues in
North American population. Although a type II error in both
Rollinson’s report and the data presented herein cannot be ruled
out, the fact that the minor allele frequency at this locus ranges
across populations from 0.16 to 0.77 (for HapMap-CEU and
HapMap YRI respectively) shows the susceptibility of this SNP to
be affected by case-control admixture and, thus, lead to type I
errors. Thus, results observed by Rademakers’ and collaborators
may represent a slant in the selection of the FTLD-TDP patients.
In summary we conclude that variation at rs5848 does not affect
the risk for developing FTLD in European populations. Although
a small effect in the FTLD-TDP pathological subtype of the
disease cannot be discarded, evidence presented here and
elsewhere does not support this idea. Further genotyping of
different populations of these and other characteristics is needed
for better understanding the role of rs5848 on the pathogenesis of
FTLD.
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